clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Whittemore KR and Cohen M Imaging and review of a large pre-auricular pilomatrixoma in a child. 2012 World J Radiol pmid:22761984
Grande M et al. Helicobacter pylori and gastroesophageal reflux disease. 2008 World J Surg Oncol pmid:18601740
Cavanna L et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. 2008 World J Surg Oncol pmid:18353178
Cindoruk M et al. Influence of H pylori on plasma ghrelin in patients without atrophic gastritis. 2007 World J. Gastroenterol. pmid:17461454
Mesquita MA et al. One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer. 2005 World J. Gastroenterol. pmid:15962376
Cosme A et al. Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. 2017 World J. Gastroenterol. pmid:28566898
Keshavarz AA et al. Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian population. 2007 World J. Gastroenterol. pmid:17352026
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Choi HS et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22654429
Kawakami E et al. Furazolidone-based triple therapy for H pylori gastritis in children. 2006 World J. Gastroenterol. pmid:17006997
Huang JQ et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. 2005 World J. Gastroenterol. pmid:15884111
Robles-Jara C et al. Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? 2008 World J. Gastroenterol. pmid:18473407
Koussoulas V et al. Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. 2007 World J. Gastroenterol. pmid:17729416
Hwang JJ et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. 2015 World J. Gastroenterol. pmid:25945019
Gumurdulu Y et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. 2004 World J. Gastroenterol. pmid:14991935
Mirbagheri SA et al. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. 2006 World J. Gastroenterol. pmid:16937475
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Ching SS et al. Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. 2008 World J. Gastroenterol. pmid:18609709
Miehlke S et al. Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). 2001 World J. Gastroenterol. pmid:11819768
Iannone A et al. New fecal test for non-invasive detection: A diagnostic accuracy study. 2018 World J. Gastroenterol. pmid:30038469
Matta AJ et al. Punctual mutations in gene of clarithromycin-resistant in Colombian populations. 2018 World J. Gastroenterol. pmid:29662291
Lee HJ et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. 2015 World J. Gastroenterol. pmid:25574111
Brennan DE et al. Can bacterial virulence factors predict antibiotic resistant infection? 2018 World J. Gastroenterol. pmid:29531461
Mamori S et al. Age-dependent eradication of Helicobacter pylori in Japanese patients. 2010 World J. Gastroenterol. pmid:20806435
Yoon JH et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. 2012 World J. Gastroenterol. pmid:23236238
Buzás GM and Józan J First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. 2006 World J. Gastroenterol. pmid:16981260
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Campuzano-Maya G Cure of alopecia areata after eradication of Helicobacter pylori: a new association? 2011 World J. Gastroenterol. pmid:21912461
Hao Q et al. New mutation points in 23S rRNA gene associated with Helicobacter pylori resistance to clarithromycin in northeast China. 2004 World J. Gastroenterol. pmid:15052698
Sargýn M et al. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. 2003 World J. Gastroenterol. pmid:12717872
Lai YC et al. Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. 2004 World J. Gastroenterol. pmid:15052680
Cianci R et al. Third-line rescue therapy for Helicobacter pylori infection. 2006 World J. Gastroenterol. pmid:16688818
Zhang L et al. Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. 2006 World J. Gastroenterol. pmid:16804982
Chang CC et al. Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils. 2005 World J. Gastroenterol. pmid:15742400
Feng LY et al. Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. 2005 World J. Gastroenterol. pmid:15742421
Zhou Q et al. Drug utilization of clarithromycin for gastrointestinal disease treatment. 2008 World J. Gastroenterol. pmid:18932287
Isomoto H et al. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15786539
Wang HH et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. 2005 World J. Gastroenterol. pmid:15786549
Shimbo I et al. Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. 2005 World J. Gastroenterol. pmid:16437727
Sugimoto M and Furuta T Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. 2014 World J. Gastroenterol. pmid:24914361
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Bustamante-Rengifo JA et al. Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. 2017 World J. Gastroenterol. pmid:28373764
Chen KY et al. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. 2015 World J. Gastroenterol. pmid:26420970
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Mohammadi M et al. Helicobacter pylori antibiotic resistance in Iran. 2005 World J. Gastroenterol. pmid:16273615
Onyekwere CA et al. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. 2014 World J. Gastroenterol. pmid:24707145
Wu JY et al. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. 2014 World J. Gastroenterol. pmid:24695835
Gao XZ et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. 2010 World J. Gastroenterol. pmid:20818821
Garza-González E et al. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. 2014 World J. Gastroenterol. pmid:24587620
Farshad S et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. 2010 World J. Gastroenterol. pmid:21128326